TCR2 Therapeutics (TCRR) Prices 8M Share Common Offering at $15.50/Sh

TCR2 Therapeutics (TCRR) PT Raised to $33 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $33.00 (from $19.00) while maintaining a Buy rating.... More

TCR2 Therapeutics (TCRR) to Offer 6M Common Shares

TCR2 Therapeutics Inc. (Nasdaq: TCRR) has commenced an underwritten public offering of 6,000,000 shares of its common stock. TCR2 also intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares... More

TCR2 Therapeutics (TCRR) PT Raised to $33 at H.C. Wainwright, After Co Releases Interim Trial Data

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $33.00 (from $19.00) while maintaining a Buy rating.

Pre-Open Stock Movers 07/27: (TCRR) (SOGO) (OCGN) Higher; (BHTG) (LMND) (HAS) Lower (more...)

Today's Pre-Open Movers

TCR2 Therapeutics Inc. (Nasdaq: TCRR) 47% HIGHER; announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed with only one patient exhibiting TC-210-related non-hematologic grade >2 toxicity and no... More

Roth Capital Upgrades TCR2 Therapeutics (TCRR) to Buy

Roth Capital analyst Tony Butler upgraded TCR2 Therapeutics (NASDAQ: TCRR) from Neutral to Buy with a price target of $35.00.

The analyst comments "TCR2 presented the first human data from its mesothelin-directed TRuC (Tcell receptor fusion construct) T-cells, TC-210, in solid tumors. Despite positive pre-clinical... More

TCR2 Therapeutics (TCRR) Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors (Earlier)

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed with only... More

TCR2 Therapeutics (TCRR) PT Raised to $45 at BMO Capital

BMO Capital analyst Do Kim raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $45.00 (from $35.00) while maintaining a Outperform rating.

The analyst commented, "We raise our estimates and target price to $45 from $35, following 2 PRs (40% ORR) in the first dose level of Phase 1.... More

TCR2 Therapeutics (TCRR) PT Raised to $32 at Wedbush

Wedbush analyst David Nierengarten raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $32.00 (from $25.00) while maintaining a Outperform rating.... More